RNU2-13P

Across TCGA pan-cancer cohorts, RNU2-13P RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RNU2-13P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU2-13P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU2-13P expression acts as an unfavorable survival marker, although some lineages such as BRCA and LUSC show a favorable association.

LIHC, UVM, and BLCA are the cancer types where RNU2-13P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.220	0.696	<.001	99	view →
UVM	OS	Tertile	II,III,IV	0.213	0.718	.002	81	view →
BLCA	OS	Tertile	IV	0.161	0.596	<.001	45	view →
SKCM	DFS	Tertile	II,III,IV	0.317	0.577	.005	39	view →
DLBC	DFS	Tertile	IV	0.120	0.683	.001	36	view →
OV	DFS	Tertile	IV	0.173	0.486	.001	36	view →
BRCA	DFS	Tertile	III,IV	0.954	0.835	.001	31	view →
THCA	DFS	Tertile	II,III,IV	0.151	0.699	.003	27	view →
CESC	OS	Tertile	All	0.568	0.805	.009	24	view →
GBM	OS	Tertile	All	0.076	0.415	<.001	18	view →
UCS	OS	Tertile	All	0.265	0.693	.016	18	view →
LUSC	DFS	Tertile	All	1.000	0.739	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

RNU2-13P–LIHC (OS)

Open the LIHC breakdown →